# Colorectal Cancer Screening Expands Beyond Colonoscopy
The American Cancer Society released updated colorectal cancer screening guidelines that broaden detection options for adults. Stool-based tests and blood tests now rank alongside colonoscopy as approved screening methods.
The change reflects two decades of technological advancement. Stool tests detect DNA markers and hemoglobin in feces that indicate cancer risk. Blood tests identify protein biomarkers associated with colorectal cancer. Both approaches reduce barriers to screening, particularly for people avoiding invasive procedures.
Colonoscopy remains the gold standard. It allows doctors to directly visualize the colon, identify polyps, and remove precancerous tissue in one procedure. However, colonoscopy requires sedation, bowel preparation, and time away from work. These factors deter many adults from screening.
The expanded options address real access gaps. Rural patients may travel hours to reach a colonoscopy facility. People with anxiety about invasive procedures often skip screening entirely. Those without insurance or with high out-of-pocket costs face financial obstacles. Stool and blood tests can be completed at home or in a doctor's office with minimal preparation.
Timing matters. The American Cancer Society recommends screening begin at age 45 for average-risk adults, down from the previous age 50. High-risk populations, including Black Americans and those with family history of colorectal cancer, should start at 40. Early detection prevents most colorectal cancers from developing.
Screening frequency depends on test type. Stool tests require annual or biennial repetition. Blood tests may require different intervals pending additional research. Colonoscopy remains effective every 10 years for people with normal results.
Doctors emphasize that any screening beats no screening. The American Cancer Society chose multiple pathways intentionally. When patients select their preferred method, screening rates increase